That stealthy single-cell sequencing startup from Flagship Pioneering now has a proper name: Cellarity.
The company, which will likely use artificial intelligence and machine-learning models to analyze data sets from single-celled sequencing and other sources, now employs about 23 employees, roughly double the number it had in December. The company will be working on drugs for cancer as well as diseases that affect the immune system and the body’s inflammatory response, according to the company’s December presentation.
About the Author Reprints
